Denali Therapeutics Inc (DNLI)

Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	100.00% -	1.267	294.12	35.14	10.28
Operating Expenses	15.22% 132.57	115.06	123.64	155.96	115.63
Benefits Costs and Expenses	-	-	-	-	-
Costs And Expenses	15.22% 132.57	115.06	123.64	155.96	115.63
Operating Income/Loss	16.50% -132.57	-113.80	170.48	-120.81	-105.34
Nonoperating Income/Loss	9.09% 13.13	14.44	12.90	11.03	6.66
Income/Loss From Continuing Operations Before Tax	100.00% -	1.267	294.12	35.14	10.28
Income Tax Expense/Benefit	0.03	-	-	-	-0.006
Income/Loss From Continuing Operations After Tax	20.25% -119.47	-99.35	183.38	-109.78	-98.68
Net Income/Loss	20.25% -119.47	-99.35	183.38	-109.78	-98.68
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	99.79% 0.2947	137.64	137.05	136.52	2.4758
Diluted Average Shares	99.79% 0.2947	137.64	140.93	136.52	2.4758
Basic Earnings Per Share	20.83% -0.87	-0.72	1.34	-0.80	-0.75
Diluted Earnings Per Share	20.83% -0.87	-0.72	1.30	-0.80	-0.75
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-